ArticleJournal of translational medicine2025
Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundBladder cancer, a widely occurring malignant tumor worldwide, is closely related to the abnormal activation of numerous signaling pathways during its initiation, progression, and metastasis. Protein kinase D2 (PRKD2), as a member of the protein kinase D family, exerts a pivotal influence on human cancers. This research aimed to elucidate the involvement and mechanism of PRKD2 in bladder cancer.
methodsPRKD2 expression was analyzed using quantitative real-time PCR, Western blotting and tissue microarray (n = 30). Functional experiments were conducted to evaluate the biological phenotypes of cells, including CCK-8 assay, colony formation assay, flow cytometry analysis, scratch wound healing assay, Transwell migration assay, and mouse xenograft model. The phosphorylation of MCM2 by PRKD2 was examined using site-directed mutagenesis and immunoprecipitation assay assays.
resultsOur results revealed markedly elevated expression levels of PRKD2 in bladder cancer compared to control tissues. Increased PRKD2 expression was associated with lymph node metastasis, distant metastasis, advanced TNM staging, and poorer prognosis. Functional experiments demonstrated that depletion of PRKD2 impeded the proliferation, migration, invasion, and epithelial-mesenchymal transition of bladder cancer cells in vitro and in vivo. Mechanistically, PRKD2 phosphorylates complex component 2 (MCM2) at serine 139. This phosphorylation drives the malignant progression of bladder cancer cells.
conclusionsThese findings offer new insights into regulatory mechanisms involving PRKD2 contributing to the malignancy of bladder cancer, thereby presenting a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.